Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1428)	3/15/2003 11:43:28 AM
From: microcapfun	Respond to of 3044

Gotcha - thanks. >>Importantly, the parental myeloma cells as well as human lung, colon and renal tumor cells were more sensitive to bortezomib-induced apoptosis under similar hypoxic conditions. These effects were specific for bortezomib, as other proteasome inhibitors and standard chemotherapeutic agents did not demonstrate increased potency under hypoxic conditions.<< In technical terms, I think this is what is called - "dumb luck". On another subject, I'd love to see MLNM pay off the convertibles with cash to get that monkey off their backs. Then do some more cutbacks, get Velcade approved, and become profitable in 2004 instead of 2006. Wouldn't the people holding the convertibles know more than we do? Doesn't MLNM have to negotiate with them? As regards Velcade approval for MM, I don't think there is any question about efficacy. I worry more about safety. But I guess it is no worse than chemo, right? Chemo preferentially kills stem cells, so I believe that you never completely recover from chemo. You permanently lose some regenerative power. What about Velcade? Does it also preferentially kill stem cells? Maybe a stupid question, but I was wondering.